Impact of olaparib vs physician's choice of new hormonal agent (pcNHA) on burden of pain in metastatic castration-resistant prostate cancer (mCRPC): PROfound.

Affiliation auteurs!!!! Error affiliation !!!!
TitreImpact of olaparib vs physician's choice of new hormonal agent (pcNHA) on burden of pain in metastatic castration-resistant prostate cancer (mCRPC): PROfound.
Type de publicationJournal Article
Year of Publication2020
AuteursSaad F, Roubaud G, Procopio G, Shore ND, Fizazi K, Thiery-Vuillemin A, Anjos Gdos, Gravis G, Joung JYoung, Matsubara N, Castellano D, Hussain MHA, Degboe A, Gresty C, Kang J, Burgents JE, De Bono JS
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume38
Date PublishedMAY 20
Type of ArticleMeeting Abstract
ISSN0732-183X